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Objectives The NLRP3/ASC inflammasome drives host
defence and autoinflammatory disorders by activating
caspase-1 to trigger the secretion of mature interleukin
(IL)-1β/IL-18, but its potential role in autoimmunity is
speculative.
Methods We generated and phenotyped Nlrp3-
deficient, Asc-deficient, Il-1r-deficient and Il-18-deficient
C57BL/6-lpr/lpr mice, the latter being a mild model of
spontaneous lupus-like autoimmunity.
Results While lack of IL-1R or IL-18 did not affect the
C57BL/6-lpr/lpr phenotype, lack of NLRP3 or ASC
triggered massive lymphoproliferation, lung T cell
infiltrates and severe proliferative lupus nephritis within
6 months, which were all absent in age-matched C57BL/
6-lpr/lpr controls. Lack of NLRP3 or ASC increased
dendritic cell and macrophage activation, the expression
of numerous proinflammatory mediators, lymphocyte
necrosis and the expansion of most T cell and B cell
subsets. In contrast, plasma cells and autoantibody
production were hardly affected. This unexpected
immunosuppressive effect of NLRP3 and ASC may relate
to their known role in SMAD2/3 phosphorylation during
tumour growth factor (TGF)-β receptor signalling, for
example, Nlrp3-deficiency and Asc-deficiency significantly
suppressed the expression of numerous TGF-β target
genes in C57BL/6-lpr/lpr mice and partially recapitulated
the known autoimmune phenotype of Tgf-β1-deficient
mice.
Conclusions These data identify a novel non-canonical
immunoregulatory function of NLRP3 and ASC in
autoimmunity.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a paradigma-
tical form of systemic autoimmunity.1 SLE is based
on genetic variants that compromise lymphocyte
death and their silent clearance.2 In SLE, aberrant
lymphocyte death triggers sterile inflammation,
costimulation and, subsequently, autoimmunisation
against nuclear autoantigens.3 This process is
driven by the adjuvant effect of endogenous nucleic
acids at Toll-like receptor (TLR)-7 and TLR-9 that
trigger interferon-α-dependent immunity.4 5 Lupus
nephritis results from immune complex disease and
is associated with progressive infiltrates of autoreac-
tive T cells, often forming tertiary lymphoid tissue
organs like in other solid organs.1 6 7
Inflammasomes are danger signalling platforms
within the cytosol of myeloid antigen-presenting
cells that integrate various pathogen-associated or
damage-associated signals into the activation of
caspase-1.8 The NACHT, LRR and PYD
domains-containing protein (NLRP)-3 inflamma-
some is comprised of NLRP3 and of apoptosis-
associated speck-like protein containing a CARD
(ASC), which first interact at their caspase recruit-
ment domain (CARD) followed by the assembly of
several such heterodimers to a wheel-like structure
that can activate caspase-1.8 Caspase-1 activation
has two major biological effects that relate to its
enzymatic activity: First, it cleaves pro-interleukin
(IL)-1β and pro-IL-18 into its mature forms. The
pyretic and proinflammatory effects of IL-1R and
IL-18R signalling imply an important role for
caspase-1 activation in host defence as well as in
autoinflammation disorders.8–11 In addition, crys-
tals or crystalline proteins specifically activate the
NLRP3 inflammasome, which unravelled the
central role of caspase-1-mediated inflammation in
crystal-related disorders.12–16 The second biological
effect of caspase-1 is DNA fragmentation and pro-
grammed cell death, referred to as pyroptosis.17 18
While the role of the NLRP3 inflammasome in
host defence and autoinflammation is obvious, its
role in autoimmunity is less clear, mostly because
IL-1β and IL-18 have diverse effects on the adap-
tive immune system.19 Some studies support a
similar proinflammatory effect on adaptive immun-
ity, as IL-1β and IL-18 promote the proliferation
and survival of Th1 and Th17 T cells and B
cells,19 20 and Nlrp3-deficient and Asc-deficient
mice are resistant to experimental autoimmune
encephalitis.21 22 In contrast, NLRP3 overexpres-
sion does not induce autoimmunity,23 24 and thera-
peutic IL-1 blockade does not consistently improve
experimental and human systemic autoimmunity in
a clinically meaningful manner, for example, in sys-
temic lupus.25–28
Given its dominant proinflammatory role in
innate immunity one would predict that the
NLRP3 inflammasome will drive antigen-
presentation, T cell priming, lymphocyte prolifer-
ation and finally, autoimmune tissue inflamma-
tion.29 30 Furthermore, nuclear lupus autoantigens
and neutrophil extracellular traps potentially con-
tribute to lupus activity by their NLRP3 agonistic
effect.31–33 To test this concept, we generated
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Nlrp3-deficient, Asc-deficient, Il-1r-deficient and Il18-deficient
C57BL/6-lpr/lpr (B6lpr) mice. Female B6lpr mice represent a
mild model of spontaneous lupus-like autoimmunity or auto-
immune lymphoproliferative syndrome34 that has proven suit-
able to identify functional roles of immunoregulatory elements
in systemic autoimmunity.35–39 We hypothesised that based on
the concept of canonical NLRP3 inflammasome signalling
Nlrp3-deficient, Asc-deficient, Il-1r-deficient and Il18-deficient




Nlrp3-deficient and Asc-deficient mice were generated and back-
crossed (F10) to the C57BL/6 strain as described.14 40
Il-1r-deficient and Il-18-deficient mice in the same genetic back-
ground were obtained from Jackson Laboratories (Bar Harbour
Maine). Nlrp3-deficient and Asc-deficient mice as well as B6lpr/lpr
mice (B6lpr) were obtained from Jackson Laboratories (Bar
Harbour, Maine). Each strain was mated with B6lpr mice to gen-
erate double heterozygote mice, which were then mated among
each other to generate double homozygous knockout and B6lpr
control mice. In each individual mouse, the genotype was assured
by PCR. Mice were housed in groups of five in sterile filter top
cages with a 12 h dark/light cycle and unlimited access to auto-
claved food and water. All mice were sacrificed by cervical dis-
location at 24 weeks of age. All experimental procedures were
performed according to the German animal care and ethics legis-
lation and had been approved by the local government
authorities.
Evaluation of autoimmune tissue injury
Spleens, lymph nodes, lungs and kidneys from all mice were
fixed in 10% buffered formalin, processed and embedded in
paraffin. The severity of the renal lesions was graded on peri-
odic acid-Schiff stained sections using the indices for activity
and chronicity as described.41 Lung and kidney fibroses were
assessed by Masson–Trichrom staining. Immunostaining was
performed as described42 using the following primary anti-
bodies: antimouse IgG and antimouse IgM (1:100, M32015,
Caltag Laboratories, Burlingame, California, USA), antimouse
C3c (complement, GAM/C3c/FITC, Nordic Immunological
Laboratories, Tilburg, Netherlands, 1:200), antimouse CD11c
(BD), antimouse CD19 (antibody-online.de), antimouse CD45
(BD), antimouse MAC2 (Cedarlane, Eching, Germany), anti-
mouse Ki67 (Dako Cytomatic, Hamburg, Germany) and anti-
mouse neutrophil (AbD SeroTec). Negative controls included
incubation with a respective isotype antibody. For quantitative
analysis, glomerular cells were counted in 10 cortical glomeruli
per section. Immunostainings of lungs and spleens were ana-
lysed using Adobe Photoshop CS4 extended for area calculation.
Serum creatine levels were determined using Jaffe method
(DiaSys Diagnostic Systems). Albuminuria was determined via
mouse Albumin Quantification Set (Bethyl Laboratories,
Montgomery, Texas, USA). Cleaved caspase-3 staining was done
on paraffin-embedded sections using cleaved caspase-3 (Asp175)
antibody (#9661, Cell signalling) in combination with antirabbit
biotin and Strept-Alexa-Fluor (Vector Laboratories Burlingame,
California, USA).
Flow cytometry
Antimouse CD3, CD4, CD8, CD25 (BD Pharmingen,
Heidelberg, Germany), foxP3 (BioLegend, San Diego, USA),
CD11c (BD), F4/80 (AbDSeroTec, Düsseldorf, Germany), CD19
(AbD), B220, CD21, CD23, IgD and IgM, antimouse κ light
chain and CD138 (BD) have been stained to differentiate T cell
and B cell subsets as well as dendritic cells and macrophages.
Major histocompatibility complex II (MHCII), (eBioscience, San
Diego, USA), CD44, CD86 (BD) and CD69 (Caltag
Laboratories, Buckingham, UK) were used as activation markers.
Intracellular labelling (foxP3 and κ light chain) was done using
Cytofix/Cytoperm kit
(BD), following the manufacturer’s instructions. Each
immune cell subset was defined at least by two different
markers. Annexin/ propidium iodide fluorescence-activated cell
sorting (PI FACS) was performed with annexinV-FITC-
apoptosis-detection-kit (BD-Bioscience) following the manufac-
turer’s instructions. Respective isotype antibodies were used to
demonstrate specific staining of cell subpopulations. Cell count-
ing beads (Invitrogen) were used for determining cell numbers
by FACS.
Real-time quantitative PCR
Real-time RT-PCR was performed on total spleen mRNA as pre-
viously described.43 SYBR Green Dye detection system was used
for quantitative RT-PCR on Light Cycler 480 (Roche,
Mannheim, Germany). Gene-specific primers (300 nM,
Metabion, Martinsried, Germany) were used as listed in online
supplementary table S1. Controls consisting of ddH2O were
negative for target and housekeeper genes. 18S rRNA was used
as a housekeeper. The PCR Arrays were performed in both
96-well plates according to the manufacturer’s protocol
(Quiagen, SABiosciences, Germany). Five housekeeping genes
including actin β, β-2 microglobulin, glyceraldehyde-3-
phosphate dehydrogenase, β-glucuronidase and heat shock
protein 90 α (cytosolic), class B member 1 were used. Standard
controls on each array for genomic DNA contamination, RNA
quality and general PCR performance were included.
Autoantibody and plasma cytokine analysis
Serum (auto-) antibody levels were determined by ELISA as
described.37 44 C57BL/6 10 week mouse serum was used as
negative control. The horseradish peroxidase (HRP) conjugated
antimouse IgG was used as secondary antibody. Serum cytokine
levels and cell culture supernatants were determined using the
commercial ELISA kits.
In vitro experiments
Bone marrow cells from wild type and knockout mice were cul-
tured with 20 ng/mL mouse recombinant granulocyte-
macrophage colony-stimulating factor (GM-CSF)/M-CSF (R&D
Systems, Wiesbaden, Germany) in Roswell Park Memorial
Institute (RPMI) medium for 7 days to generate >90% CD11c
dendritic cell subsets (DCs). On day 7, cells were harvested, sus-
pended in fresh medium and seeded at 1×106 cells/well;
1500 μL/well in 12-well plates. Stimuli were ultrapure lipopoly-
saccharide (LPS) 1 mg/mL (Invivogen, San Diego, California,
USA), CpG-DNA 1668 10 mg/mL (Invivogen, San Diego,
California, USA), imiquimod 1 mg/mL (Sequoia Research
Products Ltd, Oxford, UK) and CpG (ODN 1668; Invivogen,
San Diego, USA) for 24 h. TGF-β (1 ng/mL R&D Systems,
Minneapolis, Minnesota, USA) stimulation of bone marrow-
derived dendritic cells (BMDCs) was done for 30–45 min
before they were harvested in radioimmunoprecipitation assay
(RIPA) buffer, supplemented with phosphatase inhibitor cocktail
(Sigma Aldrich, St Louis, USA) and complete protease inhibitor
cocktail (Roche, Germany). CD19 B cells were isolated from
spleens of female B6lpr mice using B Cell Isolation Kit, followed
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by depletion of dead cells via the dead cell removal kit
(Miltenyi, Bergisch Gladbach, Germany). Purity as determined
by FACS analysis revealed over 80% purity for each isolate.
Total thymocytes were isolated according to standard protocols
from control and Nlrp3-deficient or Asc-deficient B6lpr mice.
For the differentiation of FoxP3+ regulatory T cells,
CD4CD25negative cells were purified from the spleen by
two-step magnetic cell sorting (MiltenyiBiotec). Cells were cul-
tured in complete RPMI medium with 0.0001% of
2-mercaptoethanol in flat bottom 24-well plates (1×106 cells in
1 mL) and activated with anti-CD3-CD28 beads (Invitrogen,
Darmstadt, Germany) at a bead-to-cell ratio of 1:5 in the pres-
ence of TGF-β (5 ng/mL, R&D Systems, Minneapolis,
Minnesota, USA) and IL-2 (10 ng/mL, Peprotech Hamburg,
Germany). After 72 h, the cells were stained with antimouse
CD4-PE (BD) and antimouse FoxP3-Pacific Blue (eBioscience)
antibodies for flow cytometry analysis. FoxP3 was detected
using the eBioscience Treg cell staining kit. Analysis was per-
formed using an FACS Canto II flow cytometer (BD) and
FlowJo software (TreeStar, Ashland, Oregon, USA). For analysis
of regulatory T cell function 5×104 CD4CD25negative T effector
cells were co-incubated with either 5×103 or 5×104 CD4CD25
regulatory T cells in the presence of 5×104 CD4-depleted sple-
nocytes for 3 days. Expression of CD69 on T cells and secretion
of IL-2 was determined by flow cytometry and ELISA, respect-
ively. SMAD2/3 translocation in DCs was assessed after the
staining procedure with anti-SMAD2/3 (Cell signalling, Boston,
Massachusetts, USA) following 45 min of stimulation with
TGF-β and compared using Adobe Photoshop CS4 Extended.
Western blotting
Proteins were extracted from whole spleen lysates or cultured
BMDCs homogenised in RIPA buffer (Sigma Aldrich) containing
phosphatase and proteinase inhibitor. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis and western blotting were
performed following standard procedures, using rabbit
antiphosphoSMAD2 (Ser465/467), anticleaved-caspase-3 (Cell
Signalling, Danvers, USA) or rabbit anticaspase-1 (Santa Cruz,
Heidelberg, Germany) as primary antibodies. The signal of
rabbit anti-β-actin monoclonal antibody (Cell Signalling) served
as a loading control. Secondary antibody incubation was done
with HRP conjugated antirabbit IgG (Cell Signalling) prior to
detection with enhanced chemiluminescence plus chemilumines-
cent kit (GE Healthcare Life Sciences, Freiburg, Germany).
Statistical analysis
One-way analysis of variance followed by post hoc Bonferroni’s
test was used for multiple comparisons using GraphPad Prism
V.4.03. Single groups were compared by unpaired two-tailed
Student t test. Data were expressed as mean±SEM. Statistical
significance was set at a p value of <0.05 (*); p value of <0.01
(**); p value of <0.001 (***) in comparison with control
animals.
RESULTS
NLRP3 and ASC, but not IL-1R and IL-18, protect B6lpr mice
from kidney and lung injury
Lupus nephritis is the most common organ manifestation of
SLE1 and B6lpr mice develop mild glomerulonephritis.34 Lack of
NLRP3, ASC, IL-1R or IL-18 alone did not cause any kidney
phenotype up to 12 months of age. We generated
Nlrp3-deficient, Asc-deficient, Il-1-deficient r and Il-18-deficient
B6lpr mice that bred at Mendelian ratios and common litter
sizes. At 6 months of age Nlrp3-deficient and Asc-deficient B6lpr
mice revealed diffuse mesangioproliferative glomerulonephritis
and periglomerular inflammation in kidneys of B6lpr mice, while
lack of IL-1R or IL-18 had no effect on kidney disease
(figure 1). The composite activity score for lupus nephritis was
significantly increased only in B6lpr Asc−/− and B6lpr Nlrp3−/−
mice (figure 1B) and there was a non-significant trend towards
more albuminuria (see online supplementary figure S1A). CD45
cell and Mac2 macrophage numbers inside the glomerular tufts
were significantly increased in these mutant strains only
(figure 1A, C, D). Only B6lpr Nlrp3−/− and B6lpr Asc−/− mice
showed increased glomerular deposits of complement factor
C3c and intrarenal mRNA expression of tumour necrosis factor
(TNF)-α (not shown, figure 1E), although glomerular IgG
deposits remained unaffected (figure 1F). Serum creatine levels
were increased only in B6lpr Asc−/− and B6lpr Nlrp3−/− mice,
although this reached statistical significance only for
Nlrp3-deficiency (figure 1G). Lung disease is another organ
manifestation of SLE in humans1 but usually does not affect
B6lpr mice.34 Nevertheless, Nlrp3-deficient as well as
Asc-deficient B6lpr mice developed significant peribronchial
mononuclear CD3 T cell infiltrates, while these were absent in
wild type B6lpr mice and Il-1r-deficient and Il18-deficient B6lpr
mice (see online supplementary figure S2A, B). Neither kidneys
nor lungs developed significant interstitial fibrosis in any of the
mouse strains (see online supplementary figure S1B) and also
the low neutrophil numbers as well as IL-17 gene mRNA
expression levels were genotype-independent (see online
supplementary figure S3A–D). Together, lack of NLRP3 or ASC
aggravates autoimmune nephritis and lung disease in B6lpr mice,
while Il-1r-deficient and Il-18-deficient B6lpr mice displayed no
such phenotype. These findings imply an immunoregulatory
role of ASC and NLRP3 in systemic autoimmunity that is inde-
pendent of IL-1 and IL-18.
NLRP3 and ASC, but not IL-1R and IL-18, suppress
lymphoproliferation in B6lpr mice
To unravel this unexpected finding, we first evaluated
Nlrp3-deficient, Asc-deficient, Il-1r-deficient and Il-18-deficient
mice for spontaneous autoimmunity, but up to 6 months of age
antinuclear antibodies, anti-dsDNA IgG or rheumatoid factor
could not be detected (not shown). Flow cytometry profiling of
spleen monocyte and lymphocyte populations did not reveal
any differences between the genotypes at 6 weeks and 24 weeks
of age (not shown). Next we carefully assessed the
Nlrp3-deficient, Asc-deficient, Il-1r-deficient and Il-18-deficient
B6lpr mice. Consistent with a dysfunctional inflammasome,
Nlrp3-deficient or Asc-deficient dendritic cells or macrophages
of B6lpr mice secreted reduced amounts of IL-1β in vitro (see
online supplementary figure S3). In addition, activated caspase-1
mRNA and protein levels were strongly reduced in spleens of
Nlrp3-deficient and Asc-deficient B6lpr mice as compared with
those of B6lpr control mice (figure 2A, D). This was remarkable
as other cell death-related mRNAs were increased in these two
mouse strains (figure 2A). Caspase-3 mRNA showed the stron-
gest induction but caspase-3 protein cleavage was not increased
in western blots of spleen isolates (figure 2D). Similarly, immu-
nostaining or cleaved caspase-3 positive splenocytes did not
reveal any differences among the genotypes (see online
supplementary figure S5A), arguing against enhanced splenocyte
apoptosis in Nlrp3-deficient or Asc-deficient B6lpr mice. In fact,
annexin IV flow cytometry revealed that splenocyte apoptosis
remained unaffected by the genotype (see online supplementary
figure S5B). However, lack of NLRP3 and ASC caused massive
splenomegaly and lymphadenopathy at 6 months of age, while
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total body weight was phenotype-independent (figure 2B, C).
Spleen Ki-67 staining displayed a massive increase in spleen cell
proliferation in Nlrp3-deficient and Asc-deficient B6lpr mice
compared with B6lpr controls (see online supplementary figure
S5C). This was consistent with increased total numbers of
spleen and lymph node cells quantified by flow cytometry, while
leucocyte subset percentages remained constant (data not
shown). Thus, Nlrp3-deficiency, Asc-deficiency, Il-1r-deficiency
and Il-18-deficiency do not cause autoimmunity by itself, but
aggravated nephritis in B6lpr mice lacking only NLRP3 or ASC
Figure 1 Immune complex nephritis in B6lpr mice. (A and B) Renal sections were stained with periodic acid-Schiff (PAS) or Mac2 antibodies and
signal intensity was scored applying a semiquantitativem score or quantified in glomeruli, respectively. Data are shown as means of at least 40
scored hpf from at least eight mice in each group; *p<0.05, ***p<0.001. (C) Kidney mRNA was isolated from B6lpr/Asc−/−, B6lpr/Nlrp3−/−, B6lpr/
Il-18−/−, B6lpr/Il-1r−/− and B6lpr mice. mRNA levels in kidney were analysed for tumour necrosis factor (TNF)-α. Data are shown as means of the
ratio of the specific mRNA versus that of 18S rRNA, *p<0.05. (D) Renal sections immunostaining-score was also performed for immunoglobin G
(IgG). Data are shown as means of quantification of at least 40 glomeruli from at least eight mice in each group; *p<0.05. (E) Serum creatine was
measured in all three groups of mice. The histogram presents means±SEM of at least 10 mice in each group, *p<0.05 versus B6lpr mice.
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Figure 2 Lack of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) or NACHT, LRR and PYD
domains-containing protein (NLRP3) and lymphoproliferation in B6lpr mice. (A) RNA was isolated from B6lpr/Asc−/−, B6lpr/Nlrp3−/−, B6lpr/Il-18−/−,
B6lpr/Il-1r−/− and B6lpr mice for real-time PCR analysis. Data are expressed as means of the ratio of the specific mRNA versus that of 18S rRNA
±SEM and presented as fold induction to B6lpr gene expression level; *p<0.05; **p<0.01; ***p<0.001 versus B6lpr mice. (B and C) At 6 months of
age Asc-deficient and Nlrp3-deficient B6lpr but not Il-18-deficient and Il-1R-deficient B6lpr mice revealed massive hyperplasia of cervical, axillar and
mesenteric lymph nodes as well as splenomegaly. Data are means±SEM from at least 15 mice in each group, *p<0.05; ***p<0.001. Images of B
and C are representative for at least 15 mice in each group. (D) Protein samples were prepared from spleens of 6 month-old B6lpr/Asc−/−, B6lpr/
Nlrp3−/− and B6lpr mice. Cleaved caspase-1 and cleaved caspase-3 western blots indicate the quantitative (50 mg protein load per lane) protein
expression. Histograms represent the ratio of cleaved caspase-1 and cleaved caspase-3 to the respective β-actin expression. Data are means±SEM
from at least three independent experiments, *p<0.05 versus B6lpr mice.
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was associated with hyperproliferation of lymphocytes despite
lack of caspase-1 activation and was independent of IL-1R and
IL-18. Impaired lymphocyte apoptosis could be excluded as a
causative mechanism for this phenotype (see online supplemen-
tary figure S5B).
NLRP3 and ASC suppress the activation of
antigen-presenting cells in B6lpr mice
Given the proinflammatory effects of the NLRP3 inflammasome
in innate immunity,8 45 we expected less activation of dendritic
cells and macrophages in mice. However, spleen cell flow cyto-
metry rather revealed an expansion of activated (MHC II+)
CD11c cells and F4/80+ cells in Nlrp3-deficient or Asc-deficient
B6lpr mice (figure 3A and see online supplementary figure S6A).
This was associated with increased mRNA expression levels of
numerous NF-κB-dependent proinflammatory mediators
(figure 3B). TLR signalling per se was not genotype-dependent.
TNF-α induction in spleen dendritic cells upon stimulation with
agonists to TLR4, TLR7 and TLR9 for 24 h was identical for all
genotypes (figure 3C). Also the uptake rate of dextran particles
by spleen mononuclear cells was genotype-independent (see
online supplementary figure S6B). Together, although we
expected Nlrp3-deficiency or Asc-deficiency to reduce caspase-1/
IL-1β-dependent inflammation in B6lpr mice, lack of NLRP3 and
Figure 3 Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), NACHT, LRR and PYD domains-containing
protein (NLRP3) and myeloid cell activation. (A) The total number of F4/80−/CD11c dendritic cells and CD11c-/F4/80 macrophages and their
activation in spleens was quantified by flow cytometry in all investigated genotypes of B6lpr mice as described in methods. Data represent means
±SEM from at least 10 mice in each group. *p<0.05; **p<0.01; ***p<0.001 versus B6lpr mice. (B) RNA was isolated from spleens and mRNA levels
in spleen were analysed for NF-κB genes expression, proinflammatory genes and type I interferon dependent genes. Expression levels were
quantified by real-time PCR and presented as fold induction to controls. Data are shown as means of the ratio of the specific mRNA versus that of
18S rRNA, *p<0.05; **p<0.01; ***p<0.001. (C) Spleen-derived dendritic cells were stimulated with lipopolysaccharide (LPS), imiquimod (Imi) and
CpG as described in methods. Levels of tumour necrosis factor (TNF)-α were determined in supernatants. Data represent means±SEM.
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ASC (but not of IL-1R or IL-18) was rather associated with
increased antigen-presenting cell activation and expression of
proinflammatory mediators.
NLRP3 and ASC suppress the expansion of lymphocytes in
B6lpr mice
How does the activation of antigen-presenting cells in
Nlrp3-deficient and Asc-deficient B6lpr mice affect lymphocyte
subsets? CD4 and CD8 T cells as well as CD3CD4/CD8 double
negative T cells, a cell population abnormally expanded in SLE
and thought to contribute SLE activity in B6lpr mice,46 47 were
all increased and more activated in Nlrp3-deficient and
Asc-deficient B6lpr mice, as indicated by the activation markers
CD69 and CD44 (figure 4A,B,D). CD4/CD25/FoxP3+ ‘regula-
tory’ T cells were significantly increased only in B6lpr Asc−/−
mice (figure 4C). However, Nlrp3-deficiency and Asc-deficiency
did not at all affect the capacity of Treg cells to suppress T cell
proliferation; further the TGF-β-induced differentiation of Tregs
from CD4 T cells was not impaired (figure 4E,F).
Nlrp3-deficiency and Asc-deficiency also increased the numbers
of naïve B cells, marginal zone B cells, follicular B cells, B1 cells
with increased surface expression of the activation marker
MHC-II and CD19CD69 B cells (figure 5A,B). This was asso-
ciated with increased mRNA expression of Bcl6, while other
factors that drive the proliferation and survival of B cells and
plasma cells were not much affected (figure 5B). Also in vitro
activation of TLR4, TLR7 and TLR9 in CD19 B cells was
genotype-independent (not shown). In fact, CD138 plasma cells
were not significantly expanded in both mutant mouse strains
(figure 5C). In contrast, lack of IL-1R or IL-18 did not signifi-
cantly increase these lymphocyte counts. Il-18-deficiency rather
reduced them. When analysing lymphocyte data in percentage
of all splenocytes no genotype-related differences were seen,
which implies unspecific lymphoproliferation. Finally, we phe-
notyped lymphocyte precursors in bone marrow and thymus of
Nlrp3-deficient and Asc-deficient B6lpr mice and B6lpr controls.
There was no consistent alteration of lymphocyte maturation
that could explain the observed phenotype in adult mice (data
not shown). Together, Nlrp3-deficiency or Asc-deficiency (but
not IL-1R or IL-18) deficiency is associated with abnormal
expansion of T cells (including CD4/CD8 double positive T
cells) and on several B cell subsets (but not plasma cells) in B6lpr
mice. Also the numbers of bone marrow plasma cells were not
affected by the genotypes (see online supplementary figure
S6C). This implies that NLRP3 and ASC have an immunosup-
pressive effect on T cells and B cells in B6pr mice that is inde-
pendent from their capacity to trigger IL-1 and IL-18 secretion.
Lack of NLRP3 or ASC has little effects on systemic
inflammation and autoantibody production in B6lpr mice
As Nlrp3-deficiency and Asc-deficiency had not significantly
affected plasma cell counts in B6lpr mice, we questioned
whether enhanced lymphoproliferation and T cell and B cell
activation at all translated into more IgG and autoantibody pro-
duction or systemic inflammation. Plasma levels of multiple
proinflammatory and immunoregulatory cytokines were largely
genotype-independent except for a significant increase of
IL-12p40 and IL-23 in Nlrp3-deficient B6lpr mice (figure 5E).
Interferon-α/β, IL-1β and IL-10 plasma levels were undetectable
in all genotypes. Also plasma IgG levels were comparable in all
strains (figure 5D). Among the lupus autoantibodies only
rheumatoid factor and anti-dsDNA IgG were significantly
increased in B6lpr Nlpr3−/− mice (figure 5D), the latter con-
firmed by Crithidia luciliae assay (not shown). Despite some
trends of higher antibody levels in individual mice of the
mutant strains there was no statistically significant difference
among the genotypes for the other lupus autoantibodies tested
(figure 5D). Thus, the suppressive effect of NLRP3 and ASC on
T cells and B cells in B6lpr mice does not much affect plasma
cytokine and antibody levels.
NLRP3 and ASC regulate TGF-β signalling in B6lpr mice
What could be the reason for this unexpected aggravation of
nephritis-related autoimmunity of the Nlrp3-deficient and
Asc-deficient B6lpr mice? Among the known IL-1-independent
and IL-18-independent effects of NLRP3 and ASC,45 48–50 only
their role in TGF-βR signalling (until now documented for
TGF-β-induced epithelial–mesenchymal transition in kidney epi-
thelial cells50) has the potential to explain NLRP3-related and
ASC-related immunosuppression. In fact, of Nlrp3-deficient or
Asc-deficient B6lpr mice revealed less Smad-2 phosphorylation
on western blots of spleen isolates (figure 6A), which was asso-
ciated with a reduction in TGF-β1-induced nuclear translocation
of Smad 2/3 in Asc-deficient or Nlrp3-deficient bone marrow
dendritic cells as compared with wild type dendritic cells
(figure 6B). In addition, ASC and NLRP3 were needed in den-
dritic cells for full TGF-β1-mediated suppression of IL-6 pro-
duction upon LPS stimulation (figure 6C). As a further proof of
the concept that ASC and NLRP3 are needed for TGF-R signal-
ling, spleen mRNA profiling by PCR array revealed that lack of
ASC or NLRP3 suppressed the expression of most TGF-β target
genes in B6lpr mice (figure 6D). We selected the most regulated
genes and validated their lower spleen mRNA expression levels
in comparison with B6lpr mice by RT-PCR (figure 6D). Spleen
TGF-R chain mRNA expression levels and serum TGF-β levels
excluded an upstream defect of TGF-R signalling, in fact,
TGFβR1 and TGFβR2 chains were rather induced than sup-
pressed in Nlrp3-deficient or Asc-deficient B6lpr mice (figure 6E,
F). We conclude that ASC and NLRP3 are needed for
TGF-β1-mediated Smad-2/3 phosphorylation in dendritic cells
and subsequent TGF-β target gene expression in spleens of B6lpr
mice. Hence, lack of ASC or NLRP3 (but not of IL-1R or
IL-18) impairs the immunoregulatory effect of TGF-β1 signal-
ling in B6lpr mice.
DISCUSSION
We had hypothesised that lack of NLRP3 or ASC would attenu-
ate systemic autoimmunity and lupus-like nephritis in B6lpr
mice, mainly because canonical NLRP3 inflammasome activa-
tion via caspase-1, IL-1β and IL-18 should elicit proinflamma-
tory effects.8 11 19 However, our data disprove this concept and
rather document that NLRP3 and ASC limit the expansion and
activation of antigen-presenting cells and of T cells and B cells
and, subsequently, autoimmune tissue inflammation in B6lpr
mice. Interestingly, lupus autoantibody production and immune
complex disease were hardly affected by lack of NLRP3 or ASC,
implying an immunoregulatory role of NLRP3 and ASC mainly
on cellular immunity. Obviously, the NLRP3 inflammasome has
previously unknown immunoregulatory effects in the context of
experimental SLE. Until now, aggravation of disease in
Nlrp3-deficient mice has rarely been reported. For example,
NLRP3 suppresses antitumor immunity and age-related macula
degeneration.51 52
The NLRP3 inflammasome contributes to host defence and to
autoinflammatory disorders consistently via the proinflammatory
effects of caspase-1 activation in mononuclear phagocytes. The
proinflammatory effects of caspase-1 are threefold: via pyroptosis,
a programmed form of inflammatory cell death11 and via secretion
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of IL-1β and IL-18, which trigger inflammation via IL-1R and
IL-18R signalling systemically and in many tissues.9 10 As
expected, Nlrp3-deficiency and Asc-deficiency (but not
Il-1r-deficiency or Il-18-deficiency) reduced caspase-1 activation in
B6lpr mice, hence, the associated activation of myeloid antigen-
presenting cells and the expression of numerous proinflammatory
mediators are inconsistent with what has been demonstrated in
experimental infection or sterile inflammation.11 19–23 31–33 So by
which mechanisms could Nlrp3-deficiency and Asc-deficiency
drive lymphoproliferation, immune cell activation and lupus
Figure 4 Characterisation of T cell subsets and regulatory T cell function. (A–D) Flow cytometry was used to determine the total number of
distinct T cell subsets in spleens of 6 month-old B6lpr/Asc−/−, B6lpr/Nlrp3−/−, B6lpr/Il-18−/−, B6lpr/Il-1r−/− and B6lpr mice. The histogram presents
means±SEM of at least 15 mice in each group. *p<0.05, **p<0.01, ***p<0.001 versus B6lpr mice. (E) CD4CD25negative cells (1×106) that were
isolated from the spleen of the indicated mice were stimulated with anti-CD3-CD28 beads and tumour growth factor (TGF)-β in the presence of
interleukin (IL)-2. The percentage of CD4FoxP3 cells in the culture was determined on day 3 by flow cytometry. Conditions without TGF-β were
treated with beads and IL-2 only. Error bars indicate SEM of n=3, significance was calculated in comparison with cultures with beads alone:
**p<0.01; ***p<0.001. (F) CD4CD25 and CD4CD25negative cells were isolated from the spleen of the indicated mice. For analysis of regulatory T cell
function, CD4CD25negative were stimulated with anti-CD3-CD28 beads in the presence of increasing numbers of CD4CD25 cells. After 3 days, IL-2
secretion and expression of CD69 and CD44 by the T cells were determined. Ø, T effector cells without stimulation, Teff only, conditions without
CD4CD25 cells, significance was calculated in comparison with cultures with Teff only. Error bars indicate SEM of n=3, significance was calculated in
comparison with cultures with beads alone: *p<0.05; **p<0.01; ***p<0.001.
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Figure 5 B cell subsets and antibody production in B6lpr mice. (A and C) The total number of spleen B220 cells, B220/IgM/IgD mature B cells and
κ-light chain/CD138 plasma cells were quantified in 6 month-old B6lpr, B6lprAsc−/−, B6lprNlrp3−/−, B6lpr/Il-18−/− and B6lpr/Il-1r−/− mice) by flow
cytometry. The histogram presents means±SEM of at least 15 mice in each group; *p<0.05, **p<0.01, ***p<0.001 versus B6lpr mice. (B) The total
number of spleen B220+ cells and B cell subsets were quantified in 6 month-old B6lpr, B6lprAsc−/− and B6lprNlrp3−/− mice (B220/IgM/IgD mature
B cells; B220 CD21high/CD23low marginal zone B cells; B220 CD21low/CD23high follicular B cells; B1-cells and B220/CD19/CD69 B cells) by flow
cytometry. The histogram presents means±SEM of at least 15 mice in each group; *p<0.05, **p<0.01, ***p<0.001 versus B6lpr mice. (B) mRNA
levels in spleen were analysed for B cell survival and stimulatory factors. Expression levels were quantified by real-time PCR and presented as fold
induction to controls. Data are shown as means of the ratio of the specific mRNA versus that of 18S rRNA, *p<0.05; **p<0.01; ***p<0.001 versus
B6lpr mice. (D) Mice from all groups were bled at month 6 to determine serum levels of immunoglobin G (IgG) and ds-DNA autoantibody,
autoantibodies against Smith antigen or rheumatoid factor (RF) by ELISA. Data show individual mice from each group. The mean is indicated by a
bar; *p<0.05 versus B6lpr mice. (E) B6lpr, B6lprAsc−/− and B6lprNlrp3−/− mice were bled at month 6 to determine serum levels of interleukin
(IL)-4, IL-12, IL-17, IL-21, IL-22, IL-23, monocyte chemoattractant protein-1 and tumour necrosis factor (TNF)-α. Same grey scale for groups was used
as for 6D. Data represent means±SEM from at least eight mice in each group. *p<0.05.
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nephritis in SLE-like autoimmunity in an IL-1R-independent and
IL-18-independent manner?
Our data point towards impaired TGF-βR signalling, a
process that is known to control autoimmunity because TGF-β
is an important negative regulator of the immune system.53
TGF-β is produced by leucocytes of all lineages to control the
differentiation, proliferation and activation in autocrine and
paracrine manners. As such, TGF-β is a guardian factor of
Figure 6 Lack of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and NACHT, LRR and PYD
domains-containing protein (NLRP3) and tumour growth factor (TGF)-β signalling in B6lpr mice. (A) Western blot analysis shows Smad2
phosphorylation and represents one of three independent experiments. (B) Smad2/3 translocation to the nucleus was quantified by signal intensity.
(C) Bone marrow-derived dendritic cells were stimulated with lipopolysaccharide (LPS) alone or with LPS and TGF-β. Levels of interleukin (IL)-6 were
determined in supernatants. Data represent means±SEM; ***p<0.001. (D) mRNA levels in spleen were analysed for TGF-β-dependent signalling by
Qiagen RT2 PCR profiling array. Results are presented as volcano plots. Expression levels of significantly different expressed genes were quantified by
real-time PCR and presented as fold induction to controls. Data are shown as means of the ratio of the specific mRNA versus average of five
different housekeeping genes as indicated in the Materials and Methods section, *p<0.05; **p<0.01; ***p<0.001. (E) RNA was isolated from B6lpr/
Asc−/−, B6lpr/Nlrp3−/− and B6lpr mice for real-time PCR analysis. Data are expressed as means of the ratio of the specific mRNA versus that of 18S
rRNA±SEM and presented as fold induction to B6lpr gene expression level; *p<0.05; **p<0.01; versus B6lpr mice. (F) Mice from all groups were bled
at month 6 to determine serum levels of TGF-β by ELISA. Data show means±SEM from at least eight mice in each group.
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immune tolerance and T cell-mediated autoimmunity.54 55 For
example, mice deficient in either TGF-β1 or TGF-R display
spontaneous lethal autoimmunity.56–58 Our model did not
display lethality, which is consistent with our in vitro data that
suggest a moderate modulatory effect of Nlrp3-deficiency or
Asc-deficiency rather than a complete blockade of TGF-β signal-
ling. TGF-β1-mediated immunosuppression mostly affects den-
dritic cells, macrophages and T cells,55 59 which is consistent
with our own observations in Nlrp3-deficient and Asc-deficient
B6lpr mice. For example, autoimmunity of Tgf-β1-deficient mice
depends on self-antigen presentation via enhanced MHC class II
expression,60 61 a phenomenon also observed by us in
Nlrp3-deficient and Asc-deficient B6lpr mice. In fact, dendritic
cell-specific deletion of TGF-βRII is sufficient to induce spon-
taneous multiorgan autoimmunity,62 which documents that
TGF-βR signalling in dendritic cells is sufficient to control auto-
immunity and does not necessarily require TGF-βR-mediated
immunosuppression from regulatory T cells.55 57 This is import-
ant as we could not detect any effect of Nlrp3-deficiency and
Asc-deficiency on regulatory T cell control of T cell
proliferation.
In contrast to the prominent effect of Nlrp3-deficiency and
Asc-deficiency on cellular immunity, spleen plasma cell counts
and immunoglobulin or autoantibody production were affected
to the same extent inB6lpr mice, except for somewhat higher
dsDNA antibody and rheumatoid factor levels in
Nlrp3-deficient mice. Therefore, immune complex disease, as
determined by glomerular immune complex deposits, was
genotype-independent. Immune complex-deposition is the diag-
nostic hallmark and a sine qua non for lupus nephritis,39 63 but
disease activity is also determined by infiltrating effector T cells
and macrophages.64 65 The same applies to autoimmune lung
disease inB6lpr mice, which is rather determined by de novo ter-
tiary lymphoid tissue formation in the peribronchial compart-
ment, than by immune complex disease.36 Therefore, lung
disease and nephritis could still be markedly aggravated in
Nlrp3-deficient and Asc-deficient B6lpr mice, despite negligible
effects on humoral immunity.
A similar contradictory phenotype had been found for
TLR9-deficient B6lpr mice,66 which was confirmed in several
other lupus nephritis mouse models.35 67 68 Before, numerous
in vitro and in vivo studies had documented the proinflamma-
tory and B cell mitogenic effect of TLR9 signalling,69–72 espe-
cially when stimulated with self-DNA from immune
complexes.37 73–75 Later, it was discovered that this unexpected
phenotype of TLR9-mutant mice related to a TLR7 inhibitory
effect during the early phase of SLE,76 77 while TLR9 blockade
in the subsequent progression phase of SLE attenuated autoanti-
body production and inflammatory organ manifestations.78–81
Obviously, immunostimulatory pattern recognition receptors
can elicit unexpected outcomes in autoimmunity when they spe-
cifically modulate immune tolerance and adaptive immunity in
lupus. There were very few phenotypical differences between
Nlrp3-deficient and Asc-deficient B6lpr mice that may indicate
specific immunoregulatory functions of ASC and NLRP3 inde-
pendent from each other.
In summary, in B6lpr mice NLRP3 and ASC, the two compo-
nents of the NLRP3 inflammasome, are needed to avoid exces-
sive lymphoproliferative syndrome and autoimmune tissue
injury, but this effect is independent of their canonical role in
IL-1 and IL-18 secretion. This unexpected non-canonical func-
tion of NLRP3 and ASC seems to relate to their role in TGF-βR
signalling, for example, in Smad2/3 phosphorylation. TGF-β
target gene expression is needed to regulate the activation and
expansion of myeloid antigen-presenting cells as well as most T
cell and B cell subsets. Together we conclude, the NLRP3
inflammasome suppresses cellular autoimmunity in systemic
lupus nephritis of B6lpr mice, which defines another biological
function of NLRP3 and ASC beyond pathogen recognition.82
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